Guardian Pharmacy Services (GRDN) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
11 May, 2026Leadership and management
Co-founders have deep industry experience, including prior successful exits and leadership roles in pharmacy and healthcare sectors.
Investor relations led by a seasoned equity markets professional with over 30 years of experience.
Market opportunity and positioning
Focused on the $7 billion assisted living facility (ALF) and memory care pharmacy market, serving over 1 million residents.
Holds a 13% nationwide ALF market share, serving over 140,000 ALF residents and 205,000 total residents.
Operates 54 pharmacy locations with high adoption rates (~90%) in ALFs.
Market is highly fragmented, offering significant room for expansion.
Business model and competitive advantages
Service-led, tech-enabled model with local service and centralized support, driving improved accuracy and adherence.
Proprietary technology ecosystem includes robotics, eMAR integration, and clinical intelligence platforms.
High barriers to entry due to regulatory complexity, scale requirements, and need for specialized talent.
Latest events from Guardian Pharmacy Services
- Q1 2026 revenue and net income rose, prompting higher full-year EBITDA guidance.GRDN
Q1 20266 May 2026 - Capturing 13% of the ALF pharmacy market, growth is driven by tech, service, and disciplined expansion.GRDN
44th Annual J.P. Morgan Healthcare Conference12 Apr 2026 - Annual meeting to vote on directors, executive pay, say-on-pay frequency, and auditor ratification.GRDN
Proxy filing26 Mar 2026 - Annual meeting to vote on directors, executive pay, auditor, and governance changes.GRDN
Proxy filing26 Mar 2026 - Tech-enabled ALF pharmacy leader with strong growth, profitability, and national scale.GRDN
Investor presentation23 Mar 2026 - Momentum from vaccines, M&A, and innovation drives growth amid easing IRA headwinds.GRDN
Oppenheimer 36th Annual Healthcare MedTech & Services Conference16 Mar 2026 - Raised 2026 Adjusted EBITDA guidance after strong 2025 growth and robust cash generation.GRDN
Q4 202513 Mar 2026 - Expanding market share in assisted living pharmacy through organic growth and disciplined M&A.GRDN
47th Annual Raymond James Institutional Investor Conference2 Mar 2026 - Assisted living market focus, tech-enabled growth, and IRA headwinds offset by direct payer strategy.GRDN
Stephens Annual Investment Conference3 Feb 2026